title: [Interleukin-2 immunotherapy and cutaneous manifestations].
abstract: The cutaneous manifestations which follow the administration of recombinant interleukin-2 (rIL-2) are well known, but their nature and severity have not yet been fully studied. The authors report the dermatological changes observed in 12 patients treated with rIL-2 for renal cancer. The predominant lesion was generalized erythema followed by desquamation.
authors.affiliation: Clinique Dermatologique, Hôpital Edouard Herriot, Lyon.
authors.forename: B
authors.initials: B
authors.lastname: Larbre
authors.forename: J F
authors.initials: JF
authors.lastname: Nicolas
authors.forename: Y
authors.initials: Y
authors.lastname: Sarret
authors.forename: E
authors.initials: E
authors.lastname: Tognet
authors.forename: A
authors.initials: A
authors.lastname: Mercatello
authors.forename: J
authors.initials: J
authors.lastname: Thivolet
mesh_terms: D000328:Adult; D000368:Aged; D002985:Clinical Protocols; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D004487:Edema / Q000139:chemically induced / Q000473:pathology; D004890:Erythema / Q000139:chemically induced / Q000473:pathology; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000009:adverse effects / Q000379:methods*; D007376:Interleukin-2 / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000556:secondary*; D015979:Killer Cells, Lymphokine-Activated; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
chemical_list: D007376:Interleukin-2
vernacular_title: Immunothérapie par interleukine 2 et manifestations cutanées.